CorFlow Therapeutics Achieves Key Milestones in Clinical Trials
CorFlow Therapeutics AG has successfully completed Phase 1 of its MOCA II pivotal trial for STEMI heart attack patients and has begun enrolling first patients for Phase 2. The company also received approval to start the REVITALISE randomized controlled trial in Europe and announced enhancements to its clinical leadership team.
BAAR, Switzerland–(BUSINESS WIRE)– #415Capital–CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of